| 5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas |
35 |
| An immune-related lncRNA signature for patients with anaplastic gliomas |
32 |
| Neurologic complications of immune checkpoint inhibitors |
26 |
| First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800 |
24 |
| 5-ALA and FDA approval for glioma surgery |
23 |
| Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery |
22 |
| A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker |
22 |
| Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients |
22 |
| Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma |
21 |
| The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy |
20 |
| Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity |
19 |
| Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment |
19 |
| Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201 |
19 |
| Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database |
18 |
| The modified frailty index and 30-day adverse events in oncologic neurosurgery |
18 |
| Trametinib for progressive pediatric low-grade gliomas |
18 |
| Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes |
17 |
| Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas |
16 |
| Predictors of 30-and 90-day readmission following craniotomy for malignant brain tumors: analysis of nationwide data |
16 |
| Analyzing the interactions of mRNAs, miRNAs, lncRNAs and circRNAs to predict competing endogenous RNA networks in glioblastoma |
16 |
| Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial |
15 |
| Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma |
15 |
| Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas |
15 |
| Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis |
15 |
| ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma |
14 |
| Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme |
14 |
| Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma |
13 |
| Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study |
13 |
| Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups |
13 |
| The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas |
12 |
| Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases |
12 |
| Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors |
12 |
| Venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis |
12 |
| F-18-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-na < ve gliomas: a cross-sectional study |
12 |
| Long non-coding RNA MEG3 regulates proliferation, apoptosis, and autophagy and is associated with prognosis in glioma |
12 |
| Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas |
11 |
| MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma |
11 |
| Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis |
11 |
| Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas |
11 |
| RUNX3 inhibits glioma survival and invasion via suppression of the beta-catenin/TCF-4 signaling pathway |
11 |
| Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases |
11 |
| Diagnostic accuracy of MRI texture analysis for grading gliomas |
11 |
| CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases |
11 |
| Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas |
11 |
| JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon beta plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma |
11 |
| Surgical treatment of glioblastoma in the elderly: the impact of complications |
10 |
| Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with Zr-89-Df-IAB2M anti-PSMA minibody |
10 |
| MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44 |
10 |
| Established and emerging uses of 5-ALA in the brain: an overview |
10 |
| Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery |
9 |
